Document is current

Article History

Accepted: 19 January 2025

First Online: 21 February 2025

Declarations

:

: This research was supported by a grant of the Korean Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2024-00438476). Funding for the preparation of this article was provided by Samsung Bioepis Co., Ltd. (Incheon, Republic of Korea).

: Jun Ho Jang and Bing Han have no conflicts of interest that are directly relevant to the content of this article. Austin G. Kulasekararaj reports consultancy fees/honoraria/speaker’s bureau fees from Achillion, Akari, Alexion, AstraZeneca Rare Disease, Amgen, Apellis, Biocryst, Celgene, F. Hoffmann-La Roche, Novartis, Pfizer, NovoNordisk, Samsung, Silence Therapeutics, and Ra Pharma and research funding from Celgene/BMS and Novartis. Jinah Jung and Paola Russo are employees of Samsung Bioepis.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: JHJ formulated the concept and JJ wrote the draft of the manuscript. All authors participated in editing and revising the final manuscript.